Autolus Therapeutics (AUTL) to Release Earnings on Thursday

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.24) per share and revenue of $1.59 million for the quarter.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.12. The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $2.98 million. On average, analysts expect Autolus Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Autolus Therapeutics Price Performance

Shares of NASDAQ AUTL traded down $0.10 during mid-day trading on Tuesday, reaching $1.24. 951,845 shares of the company's stock traded hands, compared to its average volume of 1,423,630. The stock has a market cap of $328.63 million, a P/E ratio of -1.01 and a beta of 1.77. Autolus Therapeutics has a 1-year low of $1.11 and a 1-year high of $5.00. The business has a 50-day simple moving average of $1.57 and a 200 day simple moving average of $2.32.

Analysts Set New Price Targets

A number of brokerages recently commented on AUTL. Wells Fargo & Company decreased their price target on Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a research report on Friday, March 21st. Truist Financial cut their price target on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Finally, Needham & Company LLC restated a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Thursday, April 10th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Autolus Therapeutics presently has a consensus rating of "Buy" and an average target price of $9.32.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.